Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CXCR5 | P32302 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8590562 | 0.84 | MME (0.39) | MMEHDAC9POLBMMP8CXCR5 | |
| SCHEMBL20738515 | 0.83 | MME (0.48) | MMEHDAC9POLBMMP8CXCR5 | |
| SCHEMBL4815892 | 0.79 | GHSR (0.45) | MME | |
| SCHEMBL21916128 | 0.74 | MME (0.47) | MMEHDAC9POLBMMP8TSHR | |
| SCHEMBL14037744 | 0.73 | HDAC9 (0.41) | HDAC9POLBNAPRTHSD17B10CXCR5 | |
| SCHEMBL25787157 | 0.73 | TSHR (0.44) | MMEHDAC9POLBMMP8TSHR | |
| SCHEMBL21916449 | 0.72 | ALDH1A1 (0.39) | MMEHDAC9MMP8 | |
| SCHEMBL4239525 | 0.71 | MME (0.44) | MMEHDAC9MMP8 | |
| SCHEMBL3373260 | 0.71 | CYP2C19 (0.42) | MMETSHR | |
| SCHEMBL7617895 | 0.70 | MME (0.41) | MMEHDAC9MMP8TSHRCXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | NYCOMED GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-1899338-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | Nycomed GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1899341-A1 | SPIRO-IMIDAZNAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | Nycomed GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006134111-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134112-A1 | SPIRO-IMIDAZNAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | GIPR, PGC, SLC10A2 | MME 2311/4885HDAC9 462/4885POLB 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.